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Abstract
Background: Progesterone plays an important role in the proliferation and differentiation of
human endometrial cells (hECs). Large-dose treatment with progesterone has been used for
treatment of endometrial proliferative disorders. However, the mechanisms behind remain
unknown.
Methods: To investigate the role of cyclin B1 in proliferation and differentiation of hECs in
menstrual cycle, the expression of cyclin B1 throughout the menstrual cycle was evaluated in hECs.
To determine the effects of progesterone on the proliferation, cell cycle progression and apoptosis
of hECs and to test if cyclin B1 is involved in these effects, progesterone and/or Alsterpaullone (Alp,
a specific inhibitor of Cyclin B1/Cdc2) were added to primary hECs. Cellular proliferation was
evaluated with MTT test, cell cycle with propidium iodide (PI) staining and flow cytometry,
apoptosis with FITC-Annexin V and the expression of cyclin B1 with Western blotting.
Results: The expression level of cyclin B1 in secretory endometria was significantly lower than in
proliferative endometria (p < 0.01). Progesterone significantly inhibited the growth of hECs in a
concentration-dependent manner (P < 0.01). The treatment with progesterone significantly
decreased the expression of cyclin B1, increased the proportions of cell in G2/M phase, and
apoptotic cells (P < 0.05 for all). The presence of Alp significantly enhanced the effects of
progesterone on cyclin B1 down-regulation, G2/M cell cycle arrest and induction of apoptosis (P <
0.01 for all).
Conclusion:  Our findings suggest that cyclin B1 is a critical factor in proliferation and
differentiation of hECs. Progesterone may inhibit cell proliferation, mediate G2/M cell cycle arrest
and induce apoptosis in hECs via down-regulating Cyclin B1.
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Background
Progesterone plays a pivotal role in female reproduction.
It modifies the effects of estrogen on the endometrium[1].
Estrogen stimulates proliferation of both glandular epi-
thelial cells and stromal cells, whereas progesterone pre-
vents this effect and induces secretory changes in
glandular epithelial cells and decidual changes in stromal
cells[2]. The balance between these two hormones plays
important roles in regulation of the menstrual cycle, ovu-
lation, implantation and pregnancy.
The potent anti-proliferative effect of progesterone has
been utilized for treatment of endometrial proliferative
disorders[3]. Clinically, progesterone has been used for
contraception and the treatment of endometrial hyperpla-
sia and adenocarcinoma as well as endometriosis [4-6]. It
is known that long term and large dose treatment with
progesterone analogs may lead to the limitation of
endometrial growth, atrophy, apoptosis and even cell
death[7]. Therapeutic use of progesterone is often associ-
ated with irregular and unwanted bleeding[1]. Recent
clinical studies have also raised concern about an
increased risk of cardiovascular disease or breast can-
cer[8]. It highlights the importance of insights from
molecular biology of progesterone action on
endometrium which may provide us with more precise
markers for progesterone actions and thus help avoid
side-effects and lead to new therapeutic proposal.
Previous studies have shown that progesterone regulates
endometrial cell proliferation and differentiation through
a nuclear receptor-mediated mechanism, such as down-
regulation of estrogen receptor[9,10]. The progesterone-
induced growth suppression of endometrial cells has also
been explained in various ways such as the elevated activ-
ity of steroid metabolizing enzymes[11], growth factors
and cytokines[12]. However, the underlying molecular
mechanisms by which progesterone negatively regulates
the growth of endometrial cells are still not fully under-
stood.
Cell proliferation is restrained through the control of the
cell cycle[13]. Cyclin B1 is the key component of the cell
cycle machinery[14]. Cyclin B1 binds to Cdc2 at the
beginning of G2 phase forming an activated cyclin B1/
Cdc2 complex and then phosphorylates its downstream
substrates which control the G2 to M transition and pro-
mote cell mitotic division[15]. Unscheduled mis-regula-
tion of cyclin B1 during the cell cycle leads to
uncontrolled cell growth and aberrant cell function[16]. It
is also reported that cyclins are functionally involved in
the rhythmic proliferation of normal human endometrial
tissue[17]. Moreover, upregulated expression of cyclin B1,
cyclin D1 and cyclin E was detected in endometrial carci-
nomas, which indicated that cyclins might be the major
cell cycle regulators involved in endometrial cell prolifer-
ation and differentiation[18]. Up to date, it is still unclear
whether cyclins are mediated in the negative regulation of
the endometrium by progesterone.
As the detection of significantly down-regulated expres-
sion of cyclin B1 in secretory endometria strongly suggests
that cyclin B1 plays an important role in proliferation and
differentiation of hECs under steroids regulation, we then
examined the effects of progesterone on the proliferation,
cell cycle progression and apoptosis of hECs and tested if
cyclin B1 is involved in these effects. In addition, we deter-
mined whether Alsterpaullone (Alp, a specific inhibitor of
Cyclin B1/Cdc2) is capable of enhancing the effects of
progesterone on cyclin B1 down-regulation, G2/M cell
cycle arrest and induction of apoptosis.
Methods
Subjects
Endometrial tissues were obtained from 18 women (at
proliferative phase) who underwent hysterectomy or hys-
teroscopy and 12 women (at middle secretory phase) who
underwent aspiration biopsy during IVF program for
benign uterine diseases in Women's Hospital, School of
Medicine, Zhejiang University. Written informed con-
sents were obtained from all subjects and the Institutional
Review Board of School of Medicine, Zhejiang University,
granted the ethical approval for the current investigation.
All the women had regular menstrual cycles and received
no hormonal treatments three months prior to the opera-
tion. Their ages ranged from 29 to 47 years. The menstrual
cycle phase was confirmed by histologic dating.
Cell culture
6 cases of endometrial tissue at proliferative phase were
minced in Hanks' solution and digested with 0.2% colla-
genase (Gibco-BRL, Gaithersburg, MD, USA) at 37°C for
50 min. The dispersed cells were filtered through a 70-mm
nylon mesh to remove the undigested tissue pieces. Cells,
containing endometrial epithelial cells and endometrial
stromal cells were collected and re-suspended in Dul-
becco's modified Eagle's medium (DMEM, Gibco-BRL)
supplemented with 10% fetal bovine serum (Invitrogen),
50 U/ml penicillin, and 50 μg/ml streptomycin in a 60-
mm or 10-mm petri dish or 24 well plate in a humidified
atmosphere of 5% CO2  at 37°C. The medium was
changed every day. Progesterone at the concentration of 1
× 10-9, 1 × 10-8, 1 × 10-7 or 1 × 10-6 M or progesterone (1 ×
10-7  M) and/or Alp (5 mM) (Calbiochem, USA) was
added and the cells were incubated for another 72 h
before specific experiments. Each experiment was
repeated at least three times.
MTT assay
MTT (3- [4, 5-dimethylthiazol-2-yl]-2, 5-diphenyl tetrazo-
lium bromide) assay was used to evaluate the cellular pro-
liferation. Briefly, after hECs were treated withReproductive Biology and Endocrinology 2009, 7:144 http://www.rbej.com/content/7/1/144
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progesterone for 72 h, 20 μl of MTT (5 mg/ml) (Sigma,
USA) was added and the cells were incubated for addi-
tional 4 h at 37°C. When the incubation finished, 200 μl
of Dimethyl sulfoxide (DMSO) was added and the optical
densities (OD) were read at 490 nm with a microplate
reader. The experiment was conducted in triplicate and
repeated three times. Inhibition rate was calculated as fol-
lowing: (1-OD sample/OD control) × 100%.
Cell cycle analysis
Cells were detached by trypsinization, washed three times
with cold PBS and fixed with 80% ethanol at 4°C for 3 h.
For propidium iodide (PI) staining, cells were washed
three times with PBS to remove trace ethanol. The pellets
were re-suspended and stained with propidium iodide
(PI) (Sigma, USA)staining solution (0.1 mg PI and 0.5
mg/ml RNase A in PBS) and incubated at 37°C for 30
min. Cells were analyzed with flow cytometry FACS EPICS
(Coulter Epics Altra flow cytometer; Beckman Coulter,
Fullerton, CA).
Detection of apoptotic cells
Cells were detached, washed and re-suspended in 200 μl
medium and fluorescently labeled by addition of 20 μl of
binding buffer and 5 μl of Annexin V-FITC (Pharmingen,
SanDiego, CA). After the incubation at room temperature
in dark for 15 min, 2 μl of PI (1 mg/mL, Invitrogen, USA)
was added and cells were applied to flow cytometry
(Coulter Epics Altra flow cytometer). A minimum of
10,000 cells with in the gated region was analyzed.
Protein extraction and Western blot analysis
Tissues and cells were washed with PBS and lysed in lysis
buffer (1× PBS, 1% Nonidet P-40, 0.5% sodium deoxy-
cholate, 0.1% SDS, 100 μg/ml phenylmethylsulfonyl flu-
oride, 100 μg/ml leupeptin). The suspension was
centrifuged at 15,000 g for 15 min at 4°C, the supernatant
was collected and protein concentrations were deter-
mined using the Bradford method. 30 μg of protein per
lane was loaded and separated on a 10% Sodium dodecyl-
sulfate (SDS)-polyacrylamide gel and transferred to Nitro-
cellulose Transfer membrane (PROTRAN, BioScience,
Germany). Membranes were incubated with blocking
buffer (50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 0.1%
Tween 20 containing 5% non-fat milk) for 1 h, and then
incubated with monoclonal mouse anti-human Cyclin B1
antibody (Santa Cruz Biotechnology, CA, USA, 1:200
dilution), polyclonal goat anti-human β-actin antibody
(Santa Cruz Biotechnology, 1:2000 dilution) in blocking
buffer overnight at 4°C. Then membranes were incubated
with appropriate secondary antibody for 1 h at room tem-
perature. The bound antibody was detected using an
enhanced chemilumiscent (ECL) detection reagent (Santa
Cruz Biotechnology) and the bands were scanned by
Expression of cyclin B1 in human endometrium detected by Western blot Figure 1
Expression of cyclin B1 in human endometrium detected by Western blot. The relative expression of cyclin B1 in 
human endometrium at the secretory phase is significantly lower than the proliferative phase (**P < 0.01).Reproductive Biology and Endocrinology 2009, 7:144 http://www.rbej.com/content/7/1/144
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Quantity One software (Bio-Rad Laboratories, Hercules,
CA, USA). Normalized densities were determined with
ratio of density of cyclin B1 to that of β-actin.
Statistical analysis
All data were presented as mean ± SD. Student's t-test or
One-way analysis of variance (ANOVA) were used to com-
pare means. A P value less than 0.05 were considered sta-
tistically significant.
Results
Expression of cyclin B1 in human endometrium
12 pairs of human endometrium at proliferative phase
and middle secretory phase were subjected to Western
blot analysis. The result showed that the relative expres-
sion of cyclin B1 in human endometrium at the secretory
phase is significantly lower than the proliferative phase (P
< 0.01) (Figure 1).
Progesterone inhibits growth of hECs
We examined the effect of progesterone on cell prolifera-
tion of primary hECs. Progesterone inhibited hECs
growth in a dose-dependent manner. Progesterone did
not inhibit hECs growth at the concentrations of 1 × 10-9
M and 1 × 10-8 M but significantly inhibited cell growth at
Inhibition of cell growth on hECs by progesterone Figure 2
Inhibition of cell growth on hECs by progesterone. 
Human endometrial cells were treated with progesterone at 
concentrations of 1 × 10-9, 1 × 10-8, 1 × 10-7 or 1 × 10-6 M 
and cell growth was evaluated with MTT. Progesterone 
inhibited hECs growth in a dose-dependent manner. (*P < 
0.05, **P < 0.01, compared with the control cells).
Decreased expression of Cyclin B1 induced by progesterone and/or Alp Figure 3
Decreased expression of Cyclin B1 induced by progesterone and/or Alp. Human endometrial cells were treated with 
progesterone and/or Alp. The expression of cyclin B1 was significantly decreased by the treatment of progesterone or proges-
terone and Alp, but not Alp alone (*P < 0.05, **P < 0.01, compared with the control cells). The levels of cyclin B1 was signifi-
cantly decreased in cells treated with progesterone and Alp compared with those treated with progesterone or Alp alone (#P 
< 0.01).Reproductive Biology and Endocrinology 2009, 7:144 http://www.rbej.com/content/7/1/144
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1 × 10-7 M and 1 × 10-6 M with inhibitory rates of 35.0%
and 70.0% respectively (P < 0.05 and P < 0.01 respectively
compared with control cells) (Figure 2).
Progesterone and/or Alp decreases the expression of 
cyclin B1
The expression of cyclin B1 was significantly decreased by
the treatment of progesterone at a concentration of 1 × 10-
7 M compared with control cells (P < 0.05), but not by the
treatment of Alp alone at a concentration of 5 mM (P >
0.05). The levels of cyclin B1 was significantly decreased
in cells treated with progesterone and Alp compared with
those treated with progesterone or Alp alone or control
cells (P < 0.01 for all) (Figure 3).
Progesterone or plus Alp mediate cell cycle arrest at G2/M 
stage
The proportion of cells in G2/M phase was significantly
increased after hECs were treated with progesterone (P <
0.05), or progesterone and Alp (P < 0.01). 8.1% of cells
were arrested in G2/M phase after the treatment of proges-
terone and 19.0% after the treatment of progesterone and
Alp. There was also significant difference between treat-
ment with progesterone alone and progesterone plus Alp
(P < 0.05) (Figure 4).
Progesterone or plus Alp induce apoptosis of hEC
The treatment with progesterone alone or progesterone
plus ALP significantly increased the amount of apoptotic
cells (P < 0.05 and P < 0.01 respectively compared with
the control cells). The proportion of apoptotic cell was
4.7% after progesterone treatment and 12.5% after treat-
ment of progesterone and Alp. There was also significant
difference between treatment with progesterone alone
and progesterone plus Alp (P < 0.01) (Figure 5).
Discussion
In the present study, we demonstrated that the expression
level of cyclin B1 in secretory endometria was significantly
lower than in proliferative endometria. Progesterone
inhibited the growth of hECs in a concentration-depend-
ent manner. The treatment with progesterone significantly
Arrest of cell cycle in G2/M phase induced by progesterone and Alp Figure 4
Arrest of cell cycle in G2/M phase induced by progesterone and Alp. Human endometrial cells were treated with pro-
gesterone alone or in combination with Alp. Cell cycles were analyzed by flow cytometry. A: Cell cycle analyzed with propid-
ium iodide (PI) staining followed by flow cytometry. B: Comparison of the proportions of cells in G2/M phase. The proportion 
of cells in G2/M phase was significantly increased after hECs were treated with progesterone or progesterone and Alp (*P < 
0.05, **P < 0.01, compared with the control cells). There was also significant difference between treatment with progesterone 
alone and progesterone plus Alp (#P < 0.05).Reproductive Biology and Endocrinology 2009, 7:144 http://www.rbej.com/content/7/1/144
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decreased the expression of cyclin B1, increased the pro-
portions of cell in G2/M phase, and apoptotic cells. In
addition, the presence of Alp enhanced the effects of pro-
gesterone on cyclin B1 down-regulation, G2/M cell cycle
arrest and induction of apoptosis. Our results indicated
that cyclinB1 played an important role in the endometrial
cell cycle progression regulated by progesterone.
Cyclin B1, the master regulator in cell proliferation, plays
an essential role in G2/M transition of mitosis in cell pro-
liferation[19,20]. They are functionally involved in the
rhythmic proliferation and differentiation of human
endometrium and their actions are related to the levels of
sex steroids in endometrium. Our experimental data con-
firmed the result of previous study that CyclinB1/Cdc2
was expressed in proliferating cells of the normal
endometrium, and the expression of these molecules were
suppressed in the secretory phase[17]. As the menstrual
cycle is controlled by the sex steroids, mainly estrogen and
progesterone, we speculated that the down-regulated
expression of cyclin B1 in secretory endometrium is
induced, at least partly, by the ascendant secretion of pro-
gesterone.
In vitro primary hECs culture confirmed the anti-prolifer-
ative effect of progesterone in endometrial cell. Our data
showed that low dose of progesterone had no evident
effect on the proliferation of hECs, but high dose of phys-
Apoptosis of hECs induced by progesterone and Alp Figure 5
Apoptosis of hECs induced by progesterone and Alp. Human endometrial cells were treated with progesterone alone 
or in combination with Alp. Apoptosis was indexed by the detection of Annexin V. A: Apoptotic cells as labeled with Annexin 
V and followed by flow cytometry. B: Comparison of the proportions of apoptotic cells. The amount of apoptotic cells was sig-
nificantly increased with the treatment of progesterone alone or progesterone plus ALP (*P < 0.05, **P < 0.01, compared with 
the control cells). There was also significant difference between treatment with progesterone alone and progesterone plus Alp 
(#P < 0.01).Reproductive Biology and Endocrinology 2009, 7:144 http://www.rbej.com/content/7/1/144
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iological level (10-7 M) [21] and an even higher level (10-
6 M) could significantly inhibit the hECs proliferation. It
is consistent with clinical application of large dose proges-
terone in treatment for endometrial proliferative disor-
ders. As abundant expression of Cyclin B1 and alteration
of the G2 pathway was reported in abnormal proliferative
endometrial tissues, such as endometrial hyperplasia,
endometrial adenocarcinoma and endometrio-
sis[16,18,19,22-24] the down-regulation of cyclin B1
detected under the treatment of progesterone could well
explain the underlying mechanism of the inhibitory effect
of progesterone on endometrial cell growth.
A few previous studies reported that the growth inhibitory
effect of progesterone in endometrial cell was induced by
the enhancement of cell cycle arrest at the G1/S
phase[25,26]. Recently, microarray analysis of progester-
one effects on endometrial cell done by Paulssen et al[27]
indicated the significantly down-regulation of cyclin B1.
In these studies, either mice endometrial epithelial cell or
human endometrial epithelial cancer cell line, Ishikawa
cells, were used as cell model. In the current study, we
used human primary endometrial cell for the treatment of
progesterone, it was more close to the human physiology.
Flow cytometry results showed that progesterone acted on
cell cycle progression by regulating G2/M transition in
hECs with the down-regulation of cyclin B1. We supposed
that some of the different findings were due to the differ-
ent cell models and progesterone types and doses used in
the separate experiments. Results from primary human
endometrial cell culture with physiological high level pro-
gesterone treatment in our experiment provided new evi-
dence of the underlying mechanism.
It is considered that endometrium apoptosis was regu-
lated by hormonal changes[28]. In the present study,
apoptosis was observed in cultured hECs and the number
of apoptotic cells was increased by the stimulation of pro-
gesterone, indicating high level progesterone induces
apoptosis of endometrial cells. As G2/M arrest and apop-
tosis are common phenomena after genetic damage of the
G2 pathway[23], we speculated that the induction of
apoptosis in hECs by progesterone was also conducted by
down-regulation of cyclin B1. This might be one of the
mechanisms of anti-proliferation and endometrial atro-
phy induction in women who receives large dose proges-
terone treatment for endometrial proliferative disorders.
The activity of cyclinB1 could be inactivated by its inhibi-
tors, resulting in cell cycle arrest. CyclinB1/cdc2 inhibi-
tors, such as Camptothecin and Paclitaxel, have been used
for the treatment of malignancies and have been demon-
strated to be effective in limiting tumor cell growth by
down-regulation of cyclinB1/cdc2[29-32]. Alsterpaullone
(Alp) is a specific inhibitor of cyclin B1/cdc2, which inac-
tivates cyclin B1/cdc2 complex and results in the arrest of
cell growth by competitively inhibiting ATP to combine
with the catalytic domain of cdc2[29,33]. Our results
showed that the presence of Alp significantly enhanced
the effects of progesterone on cyclin B1 down-regulation,
G2/M cell cycle arrest and induction of apoptosis. It fur-
ther confirmed the pivotal role of cyclin B1 in the proges-
terone active pathway in hECs. Previous studies showed
that although Alp alone induced cell arrest at G2/M phase,
the proportion was only 2-fold higher than control[29].
In the present study, the proportion of the G2/M cell cycle
arrest induced by progesterone plus Alp was around 9-
fold higher than control and 2.5-fold higher than proges-
terone only. The proportion of endometrial cell apoptosis
induced by progesterone plus Alp was 12-fold higher than
control and 3-fold higher than progesterone only. Our
results suggest that Alp could enhance the inhibitory effect
of progesterone on endometrial cell growth and apopto-
sis. Although further study is needed to clarify the mecha-
nisms involved in these effects by Alp, these findings
implicated that use of progesterone together with ingredi-
ent of cell cycle inhibitors might improve the therapeutic
effect of hyperplasia, adenocarcinoma of endometrium
and endometriosis. It will be interesting to validate this
conjecture in the further research.
Conclusion
In conclusion, progesterone may inhibit cell proliferation,
mediate G2/M cell cycle arrest and induce apoptosis in
hECs via down-regulating Cyclin B1. The presence of Alp
enhanced the effects of progesterone on cyclin B1 down-
regulation, G2/M cell cycle arrest and induction of apop-
tosis. Our findings suggest that cyclin B1 is a critical factor
in proliferation and differentiation of hECs. Progesterone
derivatives in combination with ingredient of CyclinB1
inhibitors may be a promising way for the treatment of
endometrial proliferative diseases. Future investigations
targeting the progesterone pathway on aberrant endome-
trial cell may be fruitful for developing a novel proposal
of progesterone treatment.
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